These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35590147)

  • 61. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Lipsyc-Sharf M; de Bruin EC; Santos K; McEwen R; Stetson D; Patel A; Kirkner GJ; Hughes ME; Tolaney SM; Partridge AH; Krop IE; Knape C; Feger U; Marsico G; Howarth K; Winer EP; Lin NU; Parsons HA
    J Clin Oncol; 2022 Aug; 40(22):2408-2419. PubMed ID: 35658506
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma.
    Cai Z; Chen G; Zeng Y; Dong X; Li Z; Huang Y; Xin F; Qiu L; Xu H; Zhang W; Su X; Liu X; Liu J
    Clin Cancer Res; 2019 Sep; 25(17):5284-5294. PubMed ID: 31217202
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
    Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
    JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer.
    Pellini B; Szymanski J; Chin RI; Jones PA; Chaudhuri AA
    Thorac Surg Clin; 2020 May; 30(2):165-177. PubMed ID: 32327175
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Circulating tumour DNA, a promising biomarker for the management of colorectal cancer.
    Khakoo S; Georgiou A; Gerlinger M; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2018 Feb; 122():72-82. PubMed ID: 29458792
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Circulating Tumour DNA in Melanoma-Clinic Ready?
    Tivey A; Britton F; Scott JA; Rothwell D; Lorigan P; Lee R
    Curr Oncol Rep; 2022 Mar; 24(3):363-373. PubMed ID: 35133615
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA.
    Semenkovich NP; Szymanski JJ; Earland N; Chauhan PS; Pellini B; Chaudhuri AA
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349125
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study.
    Li Y; Mo S; Zhang L; Ma X; Hu X; Huang D; Lu B; Luo C; Peng H; Cai S; Sheng W; Peng J
    Eur J Cancer; 2022 Jul; 169():198-209. PubMed ID: 35636041
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The role of circulating tumor DNA in evaluating minimal residual disease in luminal gastrointestinal malignancies.
    Ueberroth BE; Jones JC; Bekaii-Saab T
    Clin Adv Hematol Oncol; 2022 Jul; 20(7):444-455. PubMed ID: 35802877
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Circulating Tumor DNA: An Emerging Tool in Gastrointestinal Cancers.
    Alese OB; Cook N; Ortega-Franco A; Ulanja MB; Tan L; Tie J
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-20. PubMed ID: 35471832
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical application and prospect of MRD evaluation in lung cancer based on ctDNA level: A review.
    Yan X; Liu C
    Tumori; 2023 Aug; 109(4):356-362. PubMed ID: 35815471
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Assessing the Clinical Utility of Liquid Biopsies Across 5 Potential Indications From Therapy Selection to Population Screening: A Review.
    Carr DJ; Welch HG
    JAMA Intern Med; 2023 Oct; 183(10):1144-1151. PubMed ID: 37639262
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer.
    Valenza C; Trapani D; Curigliano G
    Curr Opin Oncol; 2022 Nov; 34(6):595-605. PubMed ID: 36083118
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.
    Tie J; Wang Y; Tomasetti C; Li L; Springer S; Kinde I; Silliman N; Tacey M; Wong HL; Christie M; Kosmider S; Skinner I; Wong R; Steel M; Tran B; Desai J; Jones I; Haydon A; Hayes T; Price TJ; Strausberg RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Sci Transl Med; 2016 Jul; 8(346):346ra92. PubMed ID: 27384348
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
    Garcia-Murillas I; Chopra N; Comino-Méndez I; Beaney M; Tovey H; Cutts RJ; Swift C; Kriplani D; Afentakis M; Hrebien S; Walsh-Crestani G; Barry P; Johnston SRD; Ring A; Bliss J; Russell S; Evans A; Skene A; Wheatley D; Dowsett M; Smith IE; Turner NC
    JAMA Oncol; 2019 Oct; 5(10):1473-1478. PubMed ID: 31369045
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Molecular Residual Disease-guided Adjuvant Treatment in Resected Colorectal Cancer: Focus on CIRCULATE-Japan.
    Sato S; Nakamura Y; Oki E; Yoshino T
    Clin Colorectal Cancer; 2023 Mar; 22(1):53-58. PubMed ID: 36567192
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Potential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal Adenocarcinoma.
    Cabalag CS; Yates M; Corrales MB; Yeh P; Wong SQ; Zhang BZ; Fujihara KM; Chong L; Hii MW; Dawson SJ; Phillips WA; Duong CP; Clemons NJ
    Ann Surg; 2022 Aug; 276(2):e120-e126. PubMed ID: 35737908
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
    Coombes RC; Page K; Salari R; Hastings RK; Armstrong A; Ahmed S; Ali S; Cleator S; Kenny L; Stebbing J; Rutherford M; Sethi H; Boydell A; Swenerton R; Fernandez-Garcia D; Gleason KLT; Goddard K; Guttery DS; Assaf ZJ; Wu HT; Natarajan P; Moore DA; Primrose L; Dashner S; Tin AS; Balcioglu M; Srinivasan R; Shchegrova SV; Olson A; Hafez D; Billings P; Aleshin A; Rehman F; Toghill BJ; Hills A; Louie MC; Lin CJ; Zimmermann BG; Shaw JA
    Clin Cancer Res; 2019 Jul; 25(14):4255-4263. PubMed ID: 30992300
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
    Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A
    Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.